Clinical Trial Update: A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002) [Phase 1]

View source ↗

Summary

A Phase 1, single-dose study of MK6349 in patients with Type 2 Diabetes Mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK6349

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: TERMINATED